Intellia is a leading gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system.

from http://intelliatx.com/about-us/overview/

Publications show all

Intellia Therapeutics has published 3 articles.

SEC Filings show all

8-K1210-Q510-K1D1S-11

Contact Information